SDIX stockholders approve sale of Life Science Assets to OriGene Technologies
SDIX announced that at its special meeting of stockholders, more than 65% percent of the outstanding shares entitled to vote thereon voted to approve the sale of the assets of the company’s Life Sciences and Advanced Technologies businesses to a wholly owned subsidiary of OriGene. Stockholders also voted to approve all of the additional proposals, including the amendment of the company’s certificate of incorporation to change the company’s name to Special Diversified Opportunities Inc. effective upon completion of the asset sale, as well as a non-binding proposal regarding certain transaction-related executive compensation arrangements.